Our Co-Founder and CSO Dr. Alberto Lázaro has just published a Commentary in the Kidney International Journal, the official journ...
Arch is repurposing cilastatin, a dipeptidase-1 inhibitor, as a new treatment for acute kidney injury (AKI) Cilastatin is parti...
TORONTO, June 27, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and O...
Telara Pharma (Lead coordinator, Madrid, Spain), Fundación para la Investigación Biomédica del Hospital Gregorio Marañón (FIB...